Inactive Instrument

Clinigen Group plc Stock price

Equities

CLIN

GB00B89J2419

Dynamic Chart
Clinigen Launches NaviGATE an Educational Programme for Rare Disease Patients and Organizations CI
CNX Therapeutics Limited acquired Cardioxane® (dexrazoxane), Savene® (dexrazoxane), Totect® (dexrazoxane) and Ethyol®, four cancer support therapies from Clinigen Limited. CI
Clinigen Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Adragos Pharma GmbH completed the acquisition of Lamda Laboratories S.A. from Clinigen Limited. CI
Adragos Pharma GmbH signed a definitive agreement to acquire Lamda Laboratories S.A. from Clinigen Limited. CI
Iovance Biotherapeutics, Inc. entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited for approximately £210 million. CI
Clinigen Group plc acquired Drug Safety Navigator, LLC. CI
Clinigen Notes Results from the MIROCALS Trial Investigating Low Dose Proleukin® (Aldesleukin) in Patients with Amyotrophic Lateral Sclerosis CI
Clinigen Group plc agreed to acquire Drug Safety Navigator, LLC. CI
Clinigen Expands US Site Capacity in Response to Growing Demand for Clinical Supplies Management Services CI
Triton Funds Company Completes Takeover Of Clinigen MT
Triton Fund V SCSP, Triton Fund V L.P., Triton Fund V F&F No. 5 SCSp, Triton Fund V F&F No.3 L.P., Triton Fund V F&F L.P., Triton Fund V F&F No. 2 L.P., Triton Fund V F&F 4 SCSp and Triton C Investment A L.P., managed by Triton completed the acquisition of Clinigen Group plc. CI
UK's High Court Approves Clinigen's Takeover MT
Clinigen's Fiscal H1 Profit Sinks As Sales, Administrative Costs Rise MT
Clinigen Group plc Reports Earnings Results for the Half Year Ended December 31, 2021 CI
More news
Managers TitleAgeSince
Chief Executive Officer - 10-04-30
Director of Finance/CFO - 17-03-31
Chief Operating Officer 42 20-01-03
More insiders
Clinigen Group plc is a United Kingdom-based pharmaceutical services and products company. The Company's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. It operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). It operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Clinigen Group plc - London S.E.